基于PP2A的三重冲击疗法克服了脑癌细胞中的线粒体亡抵抗
Oxana V Denisova1, Joni Merisaari1,2, Riikka Huhtaniemi1
1Turku Bioscience Centre, University of Turku and Åbo Akademi University, Finland.
Molecular oncology
|July 17, 2023
概括
针对线粒体糖解和单独的AKT途径在脑瘤中失败了. 一种新型的三重疗法,用AKT和PDK抑制剂重新激活蛋白酸酶2A (PP2A),诱导了亡,并显示了体内疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症新陈代谢 癌症新陈代谢
背景情况:
- 恶性脑瘤表现出线粒体糖解和酸-3-酶-蛋白酶B (AKT) 路径过活性的标志.
- 以前针对单独针对AKT (AKTi) 或酸盐脱酶激酶 (PDKi) 的临床试验在脑瘤患者中取得了有限的成功.
研究的目的:
- 在脑瘤模型中研究AKT和PDK联合抑制的疗效.
- 评估一种新型的三重疗法,将AKT和PDK抑制与蛋白酸酶2A (PP2A) 反激活相结合,用于脑瘤.
主要方法:
- 使用异质质母细胞瘤 (GB) 和髓母细胞瘤 (MB) 细胞系.
- 评估了对AKTi和PDKi联合治疗和三重疗法 (AKTi + PDKi + PP2A活性剂) 的细胞静止和亡反应.
- 在内GB和MB模型中进行了体内疗效研究.
主要成果:
- 联合AKT和PDK抑制导致细胞静止反应,通路关闭和亡原始化,但不是细胞死亡.
- 包括PP2A重新激活在内的三重疗法在所有测试的大脑瘤细胞模型中都表现出敏感性.
- 在体内研究证实了脑透三重组治疗在内模型中的有效性.
结论:
- 在脑瘤中,PP2A的重新激活对于将细胞静态反应转化为细胞毒性亡至关重要.
- 三重疗法机制涉及PP2A介导的线粒体氧化酸化的关闭和增加的质子泄漏.
- 这些发现支持开发针对线粒体新陈代谢的三重打击策略,以克服脑瘤治疗阻力.
相关概念视频
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
01:46Electron Transport Chain: Complex I and II
14.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.5K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:23Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K